Sympathetic overactivation is crucial in the development and progression of adverse cardiac remodelling and dysfunction. Targeted ablation of cardiac sympathetic neurons (TACSN) is an effective approach to inhibit overactivation of the sympathetic nervous system. The aim of this study was to investigate whether TACSN could suppress myocardial infarction (MI)-induced adverse cardiac remodelling and dysfunction, thereby producing protective effects. Thirty-eight dogs were randomly assigned into the sham-operated, MI or MI-TACSN group. The TACSN was induced by injecting cholera toxin B subunit-saporin compound into the stellate ganglia 1 week after MI. Five weeks after MI surgery, echocardiographic and haemodynamic parameters of cardiac function were significantly improved in the TACSN group compared with the MI group.
INTRODUCTION
Heart failure (HF) is a serious and debilitating condition with poor survival rates and continues to increase as an inefficiently managed health-care burden around the world, affecting ∼1-2% of the adult population in developed countries (Mosterd & Hoes, 2007) . Autonomic imbalance and haemodynamic abnormalities are characteristic of HF, resulting in neurohormonal activation with elevated sympathetic activity and withdrawal of vagal activity (Floras & Ponikowski, 2015; Watson, Hood, Ramchandra, McAllen, & May, 2007) . Sympathetic c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society overactivation, a hallmark of HF, is crucial in the development and progression of adverse cardiac remodelling and dysfunction, and links HF to increased cardiovascular morbidity and mortality (Triposkiadis et al., 2009) . Therefore, therapeutic targeting to block excessive sympathetic activation is potentially of great therapeutic interest for the treatment of HF.
Stellate ganglion (SG) neurons represent the main sympathetic branch of the autonomic nervous system that regulates cardiac function. Previous studies have shown that HF increases SG nerve activity and induces remodelling of cardiac ganglia (Ogawa et al., Experimental Physiology. 2018; 103:1221 -1229 wileyonlinelibrary.com/journal/eph
New Findings
• What is the central question of this study?
Can targeted ablation of cardiac sympathetic neurons suppress myocardial infarction-induced adverse cardiac remodelling and left ventricular dysfunction?
• What is the main finding and its importance?
Targeted ablation of cardiac sympathetic neurons significantly alleviated sympathetic remodelling and neuroendocrine activation, attenuated cardiac hypertrophy and fibrosis and improved left ventricular function.
Thus, targeted ablation of cardiac sympathetic neurons might have a beneficial effect on adverse postinfarction remodelling and left ventricular dysfunction.
2007; Singh et al., 2013) . Sympathectomy and SG block have been demonstrated to be effective therapeutic options in the treatment of ventricular arrhythmias and cardiac dysfunction in HF patients (Pêgo-Fernandes et al., 2010; Sun, Liu, & Qu, 2017; Vaseghi et al., 2017) . Targeted ablation of cardiac sympathetic neurons (TACSN)
is an effective approach to decrease cardiac noradrenergic drive by injection of the retrogradely transported cholera toxin B subunitsaporin (CTB-SAP) compound into the SG (Llewellyn-Smith, Martin, Arnolda, & Minson, 1999) . Previous studies have shown that CTB-SAP, which binds to GM1 gangliosides located in the plasma membranes of sympathetic preganglionic neurons, is effective at selectively ablating cardiac sympathetic preganglionic neurons and thereby reducing the number of post-ganglionic neurons in the SG and the sympathetic innervation of the ventricular myocardium, decreasing the resting, reflex and exercise-induced sympathetic activation in conscious rats (Lujan, Palani, Chen, Peduzzi, & DiCarlo, 2009; Lujan, Palani, Peduzzi, & DiCarlo, 2010) . However, it remains unknown whether TACSN suppresses myocardial infarction (MI)-induced adverse cardiac remodelling and left ventricular dysfunction, thereby producing protective effects. Therefore, the purpose of this study was to evaluate the effects of TACSN on adverse postinfarction remodelling and left ventricular dysfunction in a canine model of chronic MI.
METHODS

Ethical approval
Animal experiments were performed with approval from the Animal Grundy (2015) . One dog was housed per cage in a temperature-controlled room (22-26 • C), at 30-40% relative humidity, with a 12 h-12 h light-dark cycle and free access to water and food. All efforts were made to minimize the number of animals used in the study and their suffering.
Animal preparation
Thirty-eight adult mongrel male dogs weighing 15-20 kg were randomly divided into the following three groups: (i) Sham group (n = 8); (ii) MI group (n = 15); and (iii) MI-TACSN group (n = 15). All surgeries were performed under general anaesthesia using 3% sodium pentobarbital (Nhwa group Co., Ltd, Jiangsu, China) at an initial dose of 30 mg kg −1 (I.V.) via the dorsalis pedis vein, followed by an additional dose of 2 mg kg −1 at the end of each hour. The level of anaesthesia was monitored by checking the heart rate, respiratory rate and corneal reflex throughout the surgery. A body surface ECG was continuously recorded throughout the procedure by use of a computer-based Lab System (Lead 7000; Jinjiang Inc., Chengdu, China). A heating pad was applied to maintain core body temperature at 36.5 ± 1.0 • C. At the end of the experiment, the animals were killed with a lethal dose of sodium pentobarbital (150 mg kg −1 , I.V.).
Myocardial infarction model preparation
The MI model was prepared by intravascular injection of gelatin sponge particles in the left anterior descending coronary artery.
The whole operation was carried out in aseptic conditions in the catheterization laboratory. Briefly, after animal preparation, the right femoral artery was punctured to insert a 6 F sheath tube, and an angiographic catheter was advanced over a guide wire to the left main coronary artery for coronary arteriography. A microcatheter was advanced over a micro-guide wire to a location within the left anterior descending coronary artery below the first diagonal branch, and 
Cholera toxin B subunit-saporin injection
One week after the first surgery, the dogs in the MI-TACSN group underwent the second surgery. 
Echocardiographic and haemodynamic measurements
Transthoracic echocardiography was performed on each dog 5 weeks after first surgery. The GE Vivid q ultrasound platform (GE Healthcare, Horten, Norway) was applied with an M4S-RS probe (frequency 1.5-3.6 MHz). The dogs were anaesthetized as described in Section 2.2.
The left ventricular end-diastolic diameter, end-systolic diameter, end- 
Histological analysis
After induction of general anaesthesia, the LSG was removed, placed in 4% paraformaldehyde solution for 24 h and embedded in paraffin.
The number of LSG neurons was determined using Cresyl Violet 
Quantitative real-time PCR (RT-PCR)
Samples of left ventricular myocardium from the infarcted border zone were quickly frozen at −80 • C for RNA and protein analyses.
The total RNA was extracted from the infarcted border zone tissues using TRIzol reagent. RT-PCR analyses were applied to determine the mRNA expression of myocardial fibrosis markers, 
Western blotting
Total proteins of each sample were extracted using RIPA lysis buffer 
Serum biomarker analysis
Collection of venous blood samples was performed before the echocardiographic measurements. Enzyme-linked immunosorbent assay kits were used to measure serum noradrenaline (NA), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), angiotensin II (Ang II) and aldosterone (ALD) concentrations (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and nerve growth factor (NGF) concentrations (Nanjing Senbeijia Biological Technology, Nanjing, China).
Statistical analysis
SPSS 19.0 software was applied for statistical analysis. All continuous variables were presented as means ± SD. Differences among groups
were assessed by one-way ANOVA, followed by post hoc LSD test or
Tamhane's T2 test. Statistical significance was defined as P < 0.05.
RESULTS
In this study, all eight dogs in the sham group completed the whole experimental process. Three dogs died of ventricular fibrillation during the process of model induction, and two dogs experienced sudden death in the MI group 5 and 7 days post-MI, respectively, with the possibility of malignant ventricular arrhythmias. In the MI-TACSN group, four dogs died of ventricular fibrillation in the process of MI induction, but no dogs experienced sudden death post-MI. In addition, two dogs in the MI-TACSN group suffered serious chest infections after injection of CTB-SAP, gradually weakened and were eventually euthanized.
Number of neurons in the LSG
Representative sections stained with Cresyl Violet and TH immunofluorescence staining of the LSG are shown in Figure 1a 
Effect of TACSN on cardiac function
As shown in 
Effect of TACSN on cardiac hypertrophy
Representative sections of the infarcted border zone stained with
Haematoxylin and Eosin are shown in Figure 2a . The cross-sectional area of cells was markedly increased in the MI group compared with the Sham group (495.1 ± 89.9 versus 246.1 ± 29.2 m 2 , respectively, P < 0.05). However, TACSN dramatically reduced the increase in the cell cross-sectional area (318.7 ± 60.5 versus 495.1 ± 89.9 m 2 , P < 0.05; Figure 2b ), indicating that TACSN reduced cardiac hypertrophy.
Effect of TACSN on myocardial fibrosis
Representative Picrosirius Red-stained sections of the infarcted border zone are shown in Figure 2a . In the MI-TACSN group compared with the MI group, collagen deposition volume was significantly reduced (10.6 ± 3.4 versus 21.1 ± 4.2%, respectively, P < 0.05; Figure 2c ). Furthermore, the relative mRNAs levels of collagen I
(1.5 ± 0.6 versus 3.2 ± 0.4, P < 0.05), collagen III (1.8 ± 0.3 versus 3.6 ± 0.4, P < 0.05), TGF-(2.0 ± 0.2 versus 3.3 ± 0.2, P < 0.05) and CTGF (1.6 ± 0.1 versus 3.0 ± 0.3, P < 0.05) of the infarcted border zone in the MI-TACSN group were greatly reduced compared with the MI group (Figure 3a) . Likewise, the immunoblotting results revealed (Figure 3b and c). All these findings suggest that TACSN attenuated myocardial fibrosis in the setting of chronic MI.
TA B L E 1 Echocardiographic and haemodynamic measurements in different groups
Effect of TACSN on sympathetic reinnervation
In were significantly increased. However, these increases were markedly suppressed in the MI-TACSN group (TH, 0.6 ± 0.2 versus 1.1 ± 0.3%, respectively, P < 0.05; and GAP43, 0.5 ± 0.1 versus 1.0 ± 0.3%, respectively, P < 0.05; Figure 4 ). In addition, compared with the Sham group, the 1AR protein expression of the infarcted border zone was significantly decreased in the MI group, which was restored by TACSN treatment (Figure 3d and e).
Effect of TACSN on serum biomarker concentrations
As shown in Figure 5a -d, the MI group exhibited a significant increase in serum NA (296.7 ± 17.1 versus 213.7 ± 14.6 ng l −1 , P < 0.05), NGF (31.2 ± 3.5 versus 20.9 ± 2.8 ng l −1 , P < 0.05), Ang II (68.26 ± 4.9 versus 31.2 ± 3.5 ng l −1 , P < 0.05) and ALD (39.1 ± 6.2 versus 17.8 ± 2.6 ng l −1 , P < 0.05) concentrations compared with the Sham group. However, the concentrations of these biomarkers were dramatically decreased, to nearly normal levels, in the MI-TACSN group, which indicated that TACSN alleviated sympathetic tone and renin-angiotensin-aldosterone system (RAAS) activity. In addition, in the MI-TACSN group compared with the MI group, serum ANP (162.0 ± 18.9 versus 191.5 ± 18.6 ng l −1 , respectively, P < 0.05) and BNP (72.9 ± 6.3 versus 99.7 ± 8.9 ng l −1 , respectively, P < 0.05) levels were significantly decreased (Figure 5e and f).
DISCUSSION
In the present study, we found the following significant effects These results indicate that TACSN has a beneficial effect on adverse postinfarction remodelling and left ventricular dysfunction, which might be attributable, at least in part, to the attenuation of both sympathetic remodelling and the cardiac neuroendocrine system.
It is well known that sympathetic activity is increased in HF and aggravates the progression of cardiac remodelling and dysfunction. High cardiac sympathetic activity and increased plasma NA concentrations in patients with HF have been shown to be correlated with the severity of cardiac dysfunction (Kaye et al., 1995) .
It was previously reported that marked cardiac dilatation and pump dysfunction produced by chronic -adrenergic receptor activation can be reversed completely by withdrawal of the excessive adrenergic stimulus (Booysen, Norton, Opie, & Woodiwiss, 2012) . Accordingly, -adrenergic receptor antagonists are the first-line therapy for HF.
In the present study, TACSN significantly reduced the number of an improvement in cardiac function. As previously reported, TACSN might selectively reduce the major source of NA release to the heart (Lujan et al., 2009 (Lujan et al., , 2010 . Importantly, TACSN is a preganglionic denervation, which suggests that there would be no reinnervation.
Furthermore, TACSN does not completely eliminate catecholamine stimulation of the heart, which suggests that postdenervation supersensitivity would be reduced. In addition, this procedure might avoid limitations of sympathectomy, such as the potential for Horner's syndrome, paraesthesia, compensatory hyperhidrosis and residual A notable feature of HF is a characteristic set of molecular alterations in the components of the -adrenoceptor signalling pathway, including a decrease in 1AR density (Engelhardt, Böhm, Erdmann, & Lohse, 1996) . The decrease in expression of 1AR in HF is probably attributable to downregulation of adrenergic receptors in response to increased circulating levels of catecholamines. It seems that -adrenoceptor desensitization is a protective adaptation, which follows the increase in plasma NA concentrations (Eschenhagen, 2008 The detrimental effects of chronic sympathetic nervous system activation should be considered in the context of activation of multiple neurohormonal systems, predominantly the RAAS. The RAAS is activated in HF, and the degree of activation is correlated with the prognosis. Angiotensin II and ALD enhance the release and inhibit the uptake of NA at nerve endings (Sumners & Raizada, 1986; Weber & Purdy, 1982) . Accumulating evidence indicates that sustained RAAS activation exerts deleterious effects on the heart, because increased Ang II concentrations cause cardiomyocyte hypertrophy and myocardial fibrosis and contribute to the development of HF (Dostal, 2000; Ferreira et al., 2008; Leenen, White, & Yuan, 2001 ). Inhibitors of the RAAS have a protective effect in preventing the progression of cardiac remodelling and, in some cases, causing reverse remodelling, thereby improving cardiac function and having a positive effect on the natural history of HF (Cohn, Ferrari, & Sharpe, 2000) . In the present study, we also found that the concentrations of Ang II, aldosterone, ANP and BNP increased in dogs with chronic MI. Our findings are in agreement with previous observations where changes of neurohormonal factors during HF were shown (Díez., 2017) . More importantly, we found that TACSN could suppress the increased levels of neurohormonal factors in dogs with chronic MI. Our findings suggest that TACSN could potentially have effects in cardiovascular disease with chronic activation of the sympathetic nervous system and RAAS.
In addition to the direct effect on haemodynamics, overactivation of the sympathetic nervous system and RAAS is responsible for myocardial fibrosis. In the present study, we observed a significant increase in left ventricular collagen deposition and the protein expression of collagen I, collagen III, TGF-and CTGF in dogs with chronic MI, which was attenuated by TACSN. It has been reported previously that activation of the sympathetic nervous system may increase TGF--mediated myocardial fibrosis via the release of NA (Lijnen, Petrov, & Fagard, 2003) . Several studies have demonstrated that inhibition of sympathetic excitation by different methods prevents myocardial fibrosis in HF (Bartholomeu et al., 2008; de Man et al., 2012; Polhemus et al., 2017; Wang, Wang, Cornish, Rozanski, & Zucker, 2014) . In addition, sympathetic nervous system activation may upregulate Ang II concentrations and stimulate the synthesis of TGF- (Schultz et al., 2002) . Angiotensin II enhances the synthesis of CTGF, which further promotes myocardial fibrosis (Adam et al., 2010) .
Therefore, improvement of the neurohormonal activation status by the simultaneous inhibition of the sympathetic nervous system and RAAS might be a primary underlying mechanism by which TACSN reduces myocardial fibrosis and improves cardiac function.
The present study has several limitations. First, a previous study suggested that both the left and right stellate ganglia provide significant sympathetic innervation to the left ventricular wall (Vaseghi et al., 2012) . However, we did not observe the effects of bilateral TACSN. Second, -adrenergic receptor antagonists are currently the first-line therapy for HF. However, we did not compare the effects of TACSN with the effects of -blockade, because this procedure should at least mimic the beneficial actions of -adrenergic receptor blockade.
Third, the number of animals studied was small; however, the sample size was based upon the expectation of observing a treatment effect.
In conclusion, TACSN inhibits cardiac sympathetic remodelling and attenuates adverse postinfarction remodelling and left ventricular dysfunction in dogs. These findings suggest a potential new therapeutic strategy for patients with HF. Additional studies are required to investigate the physiological responses to this procedure further before routine clinical use.
